The Effect of OMM on Opioid Users with Chronic Low Back Pain

Danielle Cooley D.O.  
Rowan University

James Bailey D.O.  
Rowan University

Deanna Janora M.D.  
Rowan University

Catherine Fusco D.O.  
Rowan University

Kishan Patel  
Rowan University

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day

Part of the Alternative and Complementary Medicine Commons, Osteopathic Medicine and Osteopathy Commons, Pharmaceutical Preparations Commons, and the Substance Abuse and Addiction Commons

Let us know how access to this document benefits you - share your thoughts on our feedback form.

Cooley, Danielle D.O.; Bailey, James D.O.; Janora, Deanna M.D.; Fusco, Catherine D.O.; and Patel, Kishan, "The Effect of OMM on Opioid Users with Chronic Low Back Pain" (2019). Stratford Campus Research Day. 46.  
https://rdw.rowan.edu/stratford_research_day/2019/may2/46

This Event is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of Rowan Digital Works. For more information, please contact rdw@rowan.edu.
The Effect of OMM on Opioid Users with Chronic Low Back Pain

Danielle Cooley, DO; James Bailey, DO; Deanna Janora, MD; Catherine Fusco, DO; Kishan Patel, OMS-II

NeuroMusculoskeletal Institute, Rowan University School of Osteopathic Medicine, Stratford, NJ 08084

Background and Significance

In the United States, approximately 100 million adults are affected by chronic pain, which reduces their quality of life and productivity, while accounting for billions in health care costs and lost revenue.1 Opioids are considered the gold standard in the pharmacological treatment for chronic pain conditions, and prescriptions for opiates/opioids increased by 400% from 1999 to 2010.1,2 Although opioid treatment is warranted during post-surgical and acute cancer pain, physicians still commonly overprescribe opioids, which has led to addiction, high deaths rates by overdose, and the spread of communicable diseases.1 Since chronic pain is sustained by noxious sensory input originating in the musculoskeletal system, it becomes a major target for osteopathic practices.1 Osteopathic manipulative medicine (OMM) may provide the balance that patients with chronic pain seek between state-of-the-art interventions and individualized patient-centered care.3 Studies have shown the role of OMM in altering circulatory pain biomarkers, including the endogenous opioid system by β-endorphin (BE).4 Yet, any direct significant association of these changes to a therapeutic effect from OMM remains speculative. These studies acknowledge the further need for a larger sample size and a controlled prospective design to help physicians and patients make safer opioid therapy decisions.

Study Aims and Hypothesis

• Study aims: a) Does active OMM treatment result in decreased opioid medications?; b) Will OMM treatment serve as an effective adjunct for patients currently using opioids?
• Our hypothesis is that this OMM treatment protocol will help patients reduce their current opioid therapy usage over time. We predict that the treatment and control group will display statistically significant changes over time with respect to the following health scales: physical functioning, pain, and psychosocial health.

Material and Methods

• We approached 273 NMI patients on opioid therapy with chronic low back pain to participate in the study; overall, 95 patients enrolled in the study.
• We randomized the subjects into two groups: the treatment group (OMM treatment + opioid therapy) and control group (opioid therapy). The OMM treatment modalities consisted of the following: soft tissue, muscle energy (ME), myofascial release (MFR), balanced ligamentous tension (BUT), and counterstrain (CS).
• After subject attrition, there were a total of 55 subjects who completed the study: treatment group = 24, control group = 31.
• To assess the effectiveness of treatment, patients filled out two forms after each visit, approximately every 4-6 weeks for 3-6 months.
• The Wong-Baker FACES Pain Rating Scale (Figure 1) evaluated the intensity of pain, with scores from 0 to 10. The Pain and Disability Questionnaire (PDQ) measured the disability caused by pain with two components: the functional (Func: 90) and the psychosocial component (PS: 80), for a maximum score of 150.5
• The EMR records and NJR documents helped identify and track opioid usage in milligram morphine equivalents (MME) throughout the protocol.

Results: Frequencies

Table 1: Summarizing frequencies of patients who enrolled and completed the study

<table>
<thead>
<tr>
<th>Group</th>
<th>Frequency</th>
<th>Percent</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>24</td>
<td>43.6</td>
<td>55</td>
</tr>
<tr>
<td>Control</td>
<td>31</td>
<td>56.4</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>11</td>
<td>20</td>
<td>55</td>
</tr>
<tr>
<td>Female</td>
<td>44</td>
<td>80</td>
<td></td>
</tr>
</tbody>
</table>

Paired t tests : Treatment Group

Table 2: Pre and Post-study results of PDQ scores, FACES scale, and MME dosage for the treatment group. N = 24

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-study</th>
<th>Post-study</th>
<th>Correlation</th>
<th>t(23)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDQ (Func)</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td></td>
</tr>
<tr>
<td>66.56</td>
<td>14.91</td>
<td>63.10</td>
<td>17.46</td>
<td>0.70</td>
<td>1.32</td>
</tr>
<tr>
<td>PDQ (PS)</td>
<td>44.96</td>
<td>13.23</td>
<td>40.73</td>
<td>14.69</td>
<td>0.74</td>
</tr>
<tr>
<td>FACES</td>
<td>7.00</td>
<td>1.69</td>
<td>5.75</td>
<td>2.33</td>
<td>0.09</td>
</tr>
<tr>
<td>MME</td>
<td>115.33</td>
<td>83.10</td>
<td>115.67</td>
<td>76.27</td>
<td>0.98</td>
</tr>
</tbody>
</table>

Paired t tests : Control Group

Table 3: Pre and Post-study results of PDQ scores, FACES scale, and MME dosage for the control group. N = 31

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-study</th>
<th>Post-study</th>
<th>Correlation</th>
<th>t(30)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDQ (Func)</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td></td>
</tr>
<tr>
<td>62.47</td>
<td>17.50</td>
<td>59.45</td>
<td>18.00</td>
<td>0.92</td>
<td>2.30</td>
</tr>
<tr>
<td>PDQ (PS)</td>
<td>40.95</td>
<td>14.10</td>
<td>39.81</td>
<td>14.53</td>
<td>0.78</td>
</tr>
<tr>
<td>FACES</td>
<td>6.00</td>
<td>2.11</td>
<td>5.94</td>
<td>1.77</td>
<td>0.73</td>
</tr>
<tr>
<td>MME</td>
<td>128.49</td>
<td>76.24</td>
<td>127.15</td>
<td>80.69</td>
<td>0.98</td>
</tr>
</tbody>
</table>

Conclusions and Future Work

• The results indicate that there was a trend for decreases in both the PDQ (PS) and FACES scores in the treatment group; there was also a decreasing trend in the PDQ (Func) scores for the control group.
• Possible age and gender effects were tested for and did not contribute any significant variance in either group.
• There was no significant change in the MME dosages; there needs to be a more effective way to measure the patients’ medication intake in a controlled manner.
• Suggestions for future research include using the OMM intervention every two weeks over a longer period of time (~ 6 months) , substituting the PDQ with the Roland-Morris LBP questionnaire, and adding a post-study survey for patient feedback.

Acknowledgements and References

• Thank you to Dr. Robert A. Steer for the support and generous advice with the statistical analysis.
• This work was funded by the Summer Medical Research Fellowship Program (SMRF) and supported by the Neuromusculoskeletal Institute (NMI).


Figure 1: Wong-Baker FACES Pain Rating; patients mark current level of pain they are experiencing.

Figure 2: Before and after averages for the treatment (dashed) vs. control (solid) groups.

Table 1: Summarizing frequencies of patients who enrolled and completed the study

Table 2: Pre and Post-study results of PDQ scores, FACES scale, and MME dosage for the treatment group. N = 24

Table 3: Pre and Post-study results of PDQ scores, FACES scale, and MME dosage for the control group. N = 31